South Korea
· Delayed Price · Currency is KRW Genome & Company Company Description
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea.
Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities.
The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements.
In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC).
The company was founded in 2015 and is based in Seongnam-si, South Korea.
| Country | South Korea |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
Contact Details
Address: B-8F Silicon Park Seongnam-si, 13486 South Korea | |
| Phone | 82 3 1628 0150 |
| Website | genomecom.co.kr |
Stock Details
| Ticker Symbol | 314130 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |